Skip to main content
Log in

Proteinaseninhibitoren

Eine neue Ära in der Therapie der chronischen Hepatitis C

Proteinase inhibitors

A new era in the therapy of chronic hepatitis C

  • Für Sie gelesen
  • Published:
Der Gastroenterologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. Kwo PY, Lawitz EJ et al (2010) Efficacy of Boceprevir, an NS 3 protease inhibitor, in combination with peginterferon alfa 2b and Ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT 1): an open-label, randomized multicentre phase 2 trial. Lancet 376: 705–716

    Article  PubMed  CAS  Google Scholar 

  2. Hézode C, Forestier N (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1939–1950

    Article  Google Scholar 

  3. McHutchison JG, Manns MP (2009) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292–1303

    Article  Google Scholar 

Download references

Erklärung zum Interessenkonflikt

Der Autor gibt an, Reisekostenunterstützung der Firma Essex Deutschland erhalten zu haben.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Schiedermaier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiedermaier, P. Proteinaseninhibitoren. Gastroenterologe 6, 502–503 (2011). https://doi.org/10.1007/s11377-011-0591-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-011-0591-4

Navigation